Wu 2015.

Methods	Randomised controlled trial
Participants	Insomnia diagnosis criteria: PSQI score ≥ 7 Number of participants randomised: n = 78 Number of participants: n = 71 Citalopram: n = 35 Doxepin: n = 36 Age range: 45‐64 years Gender of those randomised (M/F): Citalopram: 35.9%/64.1% Doxepin: 20.5%/79.5% Race/ethnicity: not mentioned, but presumably Chinese Country: China Setting: The Jinshan Hospital of Fudan University Included: aged 45‐64 years who had not received any psychotropic drugs for ≥ 2 weeks or hormonal agents and immunomodulators in the 6 months prior to initiation of study. Excluded: severe medical conditions (cancer, cardiovascular and cerebrovascular diseases, thyroid disorders), pregnancy and lactation and mental retardation disorders. Withdrawals: 3 participants in citalopram group and 2 participants in doxepin group did not complete the study due to adverse drug reactions Baseline imbalances: 15.4% more women in doxepin group at randomisation
Interventions	Intervention: citalopram 20 mg/day, taken after breakfast Comparison: doxepin 12.5 mg/day, taken 30 min before sleep at night
Outcomes	Primary outcomes PSQI HAMA Headache, aggravated insomnia, blood pressure increase, hyperexcitability, nausea and vomiting, dizziness, palpitations, frequent urination, somnolence and numbness
Notes

AE: adverse event; CPAP: continuous positive airway pressure; DSM: Diagnostic and Statistical Manual of Mental Disorders; F: female; HAMA: Hamilton Anxiety Rating Scale; hr: hour; IGR: Investigator Global Rating; ISI: Insomnia Severity Index; lb: pounds; LOCF: last observation carried forward; LPS: latency to persistent sleep; m: male; MDD: major depressive disorder; n: number; NAW: number of awakenings; Pg: page; PLMAI: periodic limb movements associated with arousal; SF‐36: 36‐item Short Form; PSG: polysomnography; PSQI: Pittsburgh Sleep Quality Index; SD: standard deviation; SL: sleep latency; sTST: subjective total sleep time; TST: total sleep time; VAS: visual analogue score; WASO: wake after sleep onset.